$CALC Cashflow Statement | Understand Stock

$CALC

$1.31 +$0.01 (0.77%) Close

$CALC Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Depreciation
Loss on sale/disposal of assets
Noncash lease expense
Change in the fair value of warrant liability
Change in the fair value of convertible promissory notes
Change in the fair value of promissory note
Promissory note issuance costs
Transaction costs associated with warrants
Non-cash interest expense
Accretion of discount on short-term investments
Acquired in-process research and development
Impairment of capital equipment and right-of-use asset
Change in unrealized losses on investments

Changes in operating assets and liabilities:
Prepaid expenses and other current and non-current assets
Prepaid expenses, other current and non-current assets
Accounts payable
Accrued research and development
Operating lease liability
Other current and non-current liabilities
Accrued expenses and other liabilities

Net cash used in operating activities
Investing activities:
Purchase of investments
Maturity of investments
Acquisition of in-process research and development
Proceeds from sale of property and equipment
Purchases of property and equipment
Net cash provided by (used in) investing activities

Financing activities:
Payment of taxes on vested restricted stock units
Proceeds from issuance of common stock, net of issuance costs
Acquisition of stock of Graybug, net of cash
Proceeds from exercise of stock options
Merger transaction costs
Proceeds from issuance of convertible note payable, net
Proceeds from issuance of promissory note, net
Proceeds from issuance of common stock from ATM Facility, net of issuance costs
Net cash provided by financing activities

Net increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental cash flow information:
Right-of-use asset arising from the adoption of ASC 842
Acquired in process research and development in accrued liabilities
Unpaid balance for purchases of property and equipment
Costs incurred in connection with reverse merger included in accounts payable and accrued expenses
Conversion of Series A, B, C-1, C-2 and D convertible preferred stock to common stock
Property and equipment purchases included in accounts payable
Financing costs included in accounts payable
Issuance of common stock to Graybug stockholders as a result of the Merger
Short-term investments assumed in the Merger
Prepaid expenses and other current assets assumed in the Merger
Accounts payable and accrued liabilities assumed in the Merger
Conversion of C-2 warrants to common stock
Conversion of convertible promissory notes to common stock
Conversion of convertible promissory note warrants to common stock
Cash paid for interest
Financing costs included in accounts payable and accrued expenses
Restricted stock units net settlement
Reclassification of warrant liability to equity
Equipment purchases included in accounts payable

Comments